Featured
-
-
Article
| Open AccessGeneration of whole tumor cell vaccine for on-demand manipulation of immune responses against cancer under near-infrared laser irradiation
Whole autologous tumor cell vaccine (TCV) has been proposed as a tool for cancer immunotherapy. Here the authors describe the design of a TCV platform based on photothermal nanoparticle-loaded tumor cells, triggering NIR laser irradiation induced anti-tumor immune responses at the vaccination site.
- Jiaqi Meng
- , Yanlin Lv
- & Wei Wei
-
Article
| Open AccessTh17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients
The folate receptor alpha (FRα) is overexpressed in the majority of high-grade serous ovarian cancers and has been proposed as a candidate vaccine antigen. Here the authors report the safety and immunogenicity of Th17-inducing dendritic cells pulsed with FRα-derived epitopes in an early phase I clinical trial with ovarian cancer patients.
- Matthew S. Block
- , Allan B. Dietz
- & Martin J. Cannon
-
Article
| Open AccessRepeat vaccination reduces antibody affinity maturation across different influenza vaccine platforms in humans
Here, Khurana et al. report the results of a phase 4 clinical trial with three FDA approved influenza vaccines and show that repeat influenza vaccination results in reduced antibody affinity maturation to hemagglutinin domain 1 irrespective of vaccine platform.
- Surender Khurana
- , Megan Hahn
- & Hana Golding
-
Article
| Open AccessNotch-mediated conversion of activated T cells into stem cell memory-like T cells for adoptive immunotherapy
Tumour-specific T cells can be expandedin vitroand adoptively transferred for therapy, but this strategy is limited by induction of short-lived T cell populations. Here the authors activate Notch signalling in cultured mouse or human T cells, resulting in the production of a long-lived stem cell memory T cell population that can fight tumours in mice.
- Taisuke Kondo
- , Rimpei Morita
- & Akihiko Yoshimura
-
Article
| Open AccessTargeting dendritic cells to accelerate T-cell activation overcomes a bottleneck in tuberculosis vaccine efficacy
A delay in T cell responses is postulated as a possible explanation for the limited efficacy of vaccines against tuberculosis. Here the authors demonstrate this T-cell block and remove it by activating endogenous dendritic cells or delivering activated dendritic cells to the lungs, enhancing immunity of mice toMycobacterium tuberculosis.
- Kristin L. Griffiths
- , Mushtaq Ahmed
- & Shabaana A. Khader